Company Website: http://www.biocept.com/
Biocept Inc (BIOC) Recent Headlines
What Makes Biocept (BIOC) a New Buy Stock
Biocept (BIOC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Biocept Announces Pricing of $7.5 Million Underwritten Public Offering
SAN DIEGO, Feb. 8, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock and warrants to purchase up to 6,250,000 shares of the Company's common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined price to the public of $1.20 per share and warrant. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $7.5 million.
Biocept Announces Agreement with Agiomix FZ-LLC for Target Selector Liquid Biopsy Kits
SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy solutions, announces that it has entered into an agreement with Agiomix FZ-LLC ("Agiomix"), a provider of genomics sample and bioinformatics services to customers around the world for both research and clinical applications. Under the agreement, Agiomix plans to validate Biocept's patented and proprietary liquid biopsy technology in order to perform testing for the detection of tumor biomarkers.
SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a peer-reviewed article featuring a case series of three patients indicating the clinical utility of Biocept's Target Selector™ circulating tumor DNA (ctDNA) testing in the management of patients with advanced non-small cell lung cancer (NSCLC). In each of the three patient cases, Biocept's liquid biopsy testing detected activating EGFR mutations where tissue biopsy was inadequate, and targeted EGFR-directed therapy was subsequently administered.
Biocept, Inc., Pipeline Review, Upcoming Catalysts and Milestones
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Biocept, Inc. (BIOC), a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. Biocept is an emerging player in the liquid biopsy space and the key for Biocept is to continue to raise awareness about its technology platform.
SAN DIEGO, Jan. 28, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of research-use-only (RUO) kits, which are intended to enable molecular laboratories around the world to utilize Biocept's Target Selector™ circulating tumor DNA (ctDNA) assays to perform liquid biopsy testing. Biocept's Target Selector™ platform is patent protected in the United States and in 10 major international territories. The first available kit is for the high-sensitivity detection of EGFR oncogene mutations, which are among the most frequently evaluated biomarkers for lung cancer.
Should You Worry About Biocept, Inc.’s (NASDAQ:BIOC) CEO Salary Level?
Mike Nall has been the CEO of Biocept, Inc. (NASDAQ:BIOC) since 2013. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll Read More...
Biocept Announces Pricing of $2.2 Million Registered Direct Offering
SAN DIEGO, Jan. 18, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.2 million of its common stock in a registered direct offering. The purchase price for one share of common stock will be $2.25. Under the terms of the purchase agreement, Biocept has agreed to sell approximately 990,000 shares of its common stock.
Today's Research Reports on Trending Tickers: Adamis Pharmaceuticals and Biocept
NEW YORK, NY / ACCESSWIRE / January 17, 2019 / Despite concerns of a partial government shutdown, U.S. markets extended gains for the second consecutive session on Wednesday on strong earnings from Bank ...
Today's Research Reports on Trending Tickers: Biogen and Biocept
NEW YORK, NY / ACCESSWIRE / December 19, 2018 / Shares of Biogen were continuing to slump on Tuesday after a slight recovery on Monday from last week’s descent. The company and Alkermes plc recently announced that Alkermes has submitted a New Drug Application to the FDA for diroximel fumarate (BIIB098). Shares of Biocept were soaring on high volume on news that the company has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc.
Biocept Inc (BIOC) Research Links
Biocept Inc (NASDAQ: BIOC) Stock Message Board
